Liraglutide

At a glance

---

What is liraglutide?

Liraglutide is a synthetic peptide drug that mimics GLP-1 (glucagon-like peptide-1), a hormone your gut naturally releases after eating. It's a 31-amino-acid chain with 97% structural homology to native human GLP-1 — more similar to the natural hormone than any other approved GLP-1 drug.^[5]

Developed by Novo Nordisk in Denmark, liraglutide was the molecule that proved the GLP-1 class could work as a practical medicine. Native GLP-1 is destroyed within about 2 minutes by an enzyme called DPP-4, making it useless as a drug. Novo Nordisk's solution was two modifications:

• Arg at position 34: Prevents fatty acid binding at an unintended site
• C-16 fatty acid (palmitic acid) at Lys26: Enables albumin binding in the blood, which acts as a slow-release reservoir and extends the half-life to approximately 13 hours

This 13-hour half-life made once-daily dosing possible — a significant advance over the first GLP-1 drugs (like exenatide), which required twice-daily injections. But it was still far shorter than the 7-day half-life that Novo Nordisk would later achieve with semaglutide by switching to a C-18 fatty diacid.

Liraglutide is sold under two brand names: Victoza (for type 2 diabetes, approved 2010) and Saxenda (for chronic weight management, approved 2014). It is also the only GLP-1 receptor agonist approved for adolescents aged 12 and older with obesity (December 2020).^[8]

The pioneer story matters. Liraglutide was the drug that generated the first cardiovascular outcomes data for the GLP-1 class (LEADER, 2016). It was the evidence from LEADER that convinced the medical community — and the FDA — that GLP-1 agonists weren't just glucose-lowering drugs, but cardiovascular medicines. Without liraglutide, semaglutide's path to approval would have looked very different.

---

How it works

In plain terms, liraglutide tells your body three things: release more insulin (but only when blood sugar is already high), slow down digestion so you feel full longer, and reduce appetite signals in the brain. The mechanism is identical to semaglutide — the difference is how long the drug stays active in the body.

Detailed mechanism (for advanced readers)

Liraglutide is a selective GLP-1 receptor agonist. Its mechanisms of action include:

• Glucose-dependent insulin secretion: Activates GLP-1 receptors on pancreatic beta cells, potentiating insulin release only when glucose is elevated. This glucose-dependent mechanism means liraglutide alone rarely causes hypoglycemia — a key safety advantage over sulfonylureas and insulin.
• Glucagon suppression: Inhibits glucagon release from pancreatic alpha cells, reducing hepatic glucose production. This effect is also glucose-dependent.
• Gastric emptying delay: Slows gastric motility, contributing to both post-prandial glucose reduction and increased satiety. This is also the primary driver of GI side effects (nausea, vomiting). Notably, the gastric emptying effect of liraglutide shows tachyphylaxis (diminishes over time), while the weight loss effect persists.^[5]
• Central appetite regulation: Acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger and increase satiety. This central effect is the primary driver of weight loss at the 3.0 mg dose (Saxenda).
• Cardiovascular effects: Anti-inflammatory effects on vasculature, reduced atherogenesis, improvements in lipid profiles and blood pressure. The LEADER trial demonstrated these are clinically meaningful.

How it differs from related compounds:

• vs. Semaglutide (Ozempic/Wegovy): Liraglutide uses a C-16 palmitic acid for albumin binding; semaglutide uses a C-18 fatty diacid. This single chemical difference explains the half-life gap: ~13 hours (daily dosing) vs. ~7 days (weekly dosing). Semaglutide also has an Aib8 substitution that provides additional DPP-4 resistance. Net result: semaglutide produces roughly twice the weight loss (~15% vs. ~8%).
• vs. Tirzepatide (Mounjaro/Zepbound): Liraglutide is a pure GLP-1 agonist; tirzepatide is a dual GIP/GLP-1 agonist. Tirzepatide achieves even greater weight loss (~20%) through dual receptor activation.
• vs. Exenatide (Byetta): Liraglutide has greater structural homology to native GLP-1 (97% vs. ~53%) and a longer half-life. This translates to superior glycemic control and weight loss in head-to-head trials.

---

What the research says

Liraglutide was the GLP-1 receptor agonist that proved the class could reduce cardiovascular events — not just blood sugar. The LEADER trial's 9,340 patients made it possible for semaglutide, tirzepatide, and the entire incretin class to be taken seriously as cardiovascular medicines.

Research timeline

Liraglutide's research spans nearly two decades, from early dose-finding studies through the landmark LEADER cardiovascular outcomes trial:

Key clinical trials

Liraglutide's clinical evidence base includes the SCALE program for weight management, the LEAD program for diabetes, and the landmark LEADER cardiovascular outcomes trial:

---

What the evidence shows

Like semaglutide, the claims about liraglutide are largely supported by strong clinical evidence. Here's the evidence behind the most common questions:

---

Safety & side effects

Liraglutide has one of the longest safety track records in the GLP-1 class — over 15 years of post-marketing surveillance from millions of prescriptions worldwide. The side effect profile is well-characterized and similar to other GLP-1 receptor agonists.^[9]

Common side effects (from clinical trials)

Gastrointestinal effects are the most common and are dose-dependent. They typically peak during dose escalation and improve over 4-8 weeks:

• Nausea: ~40% (vs. ~14% placebo) — the most common side effect
• Diarrhea: ~21%
• Constipation: ~19%
• Vomiting: ~16%
• Headache: ~14%
• Dyspepsia: ~9%
• Fatigue: ~8%
• Injection site reactions: ~13% (mild)

Serious safety concerns

• Pancreatitis: Rare but documented. Cases of acute pancreatitis have been reported. Liraglutide should be discontinued if pancreatitis is suspected.
• Gallbladder disease: Increased risk of cholelithiasis (gallstones), particularly with higher doses used for weight management.
• Acute kidney injury: Reported, likely secondary to dehydration from severe GI side effects. Adequate hydration is essential.
• Hypoglycemia: Low risk when used alone; increased risk when combined with insulin or sulfonylureas.
• Heart rate increase: Mean increase of 2-3 bpm observed in clinical trials. Clinical significance is uncertain.

What makes liraglutide's safety data notable

Contraindications and drug interactions

Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis
• Hypersensitivity to liraglutide or excipients
• Pregnancy (Category X — teratogenic in animal studies)

Drug interactions:

• Insulin / sulfonylureas: Increased hypoglycemia risk; dose reduction often needed
• Oral medications: Delayed gastric emptying may affect absorption of co-administered drugs
• Warfarin/anticoagulants: More frequent INR monitoring recommended during initiation
• Oral contraceptives: Potential reduced absorption; patients should be counseled accordingly

---

How people use it

Like semaglutide, liraglutide has FDA-approved dosing protocols validated in large clinical trials. Both formulations require gradual dose escalation to minimize GI side effects.

FDA-approved dosing — Victoza (type 2 diabetes)

FDA-approved dosing — Saxenda (weight management)

Administration

• Subcutaneous injection (both Victoza and Saxenda): Abdomen, thigh, or upper arm. Once daily, at any time of day, with or without food. Comes in a pre-filled pen — no reconstitution needed.
• Daily vs. weekly: This is the key practical difference from semaglutide. Some patients prefer the daily ritual; others find weekly dosing more convenient. Neither approach is inherently better — it's a matter of preference and clinical response.

Who might still choose liraglutide over semaglutide

• Adolescents (12-17): Saxenda is the only GLP-1 RA approved for this age group
• Daily dosing preference: Some patients and clinicians prefer the ability to adjust dose daily
• Cost considerations: Saxenda may be available at lower out-of-pocket cost depending on insurance
• Established safety record: 15+ years of post-marketing data vs. ~9 years for semaglutide
• Prescriber familiarity: Many endocrinologists have extensive experience with liraglutide

---

Legal & regulatory status

As of March 2026:

FDA-approved indications

Liraglutide is an FDA-approved prescription drug with multiple approved indications across two brand names:

WADA / USADA status

Liraglutide is not prohibited under WADA anti-doping rules. It has been on WADA's Monitoring Program since 2024, alongside other GLP-1 receptor agonists. Athletes will NOT receive anti-doping violations for liraglutide use.

Insurance and access

• Most commercial insurance covers Victoza for type 2 diabetes
• Coverage for Saxenda (weight management) is expanding but inconsistent
• Without insurance: Victoza ~$900-1,100/month, Saxenda ~$1,300-1,400/month
• Manufacturer savings cards may reduce copays for eligible commercially insured patients

---

How liraglutide compares

Liraglutide vs. Semaglutide (the most important comparison)

The comparison to semaglutide is inevitable — semaglutide is literally liraglutide's successor from the same company. Here's how they differ:

The chemistry is instructive: both drugs start from the same GLP-1(7-37) backbone. Semaglutide adds an Aib8 substitution for DPP-4 resistance and uses a C-18 fatty diacid instead of liraglutide's C-16 palmitic acid. That seemingly small chemical change — two extra carbon atoms and a diacid instead of monoacid — is what enables the jump from daily to weekly dosing and from 8% to 15% weight loss.^[5]

Liraglutide in the evidence hierarchy

To understand where liraglutide sits in the broader peptide evidence landscape:

Liraglutide sits near the top of the evidence hierarchy for any peptide therapy. Its evidence base is slightly smaller than semaglutide's — but it's still orders of magnitude beyond most peptides discussed online. When someone offers you a "GLP-1 alternative" that is a research compound, this is the standard it should be measured against.

---

Related content

Peptide

Semaglutide Profile

Liraglutide's next-generation successor. Longer half-life, greater weight loss, and the most extensive evidence base of any GLP-1 agonist.

Guide

How to Evaluate a Peptide Clinic

A scorecard for evaluating prescribers and clinics offering GLP-1 receptor agonists like liraglutide.

Tool

Price Comparison Worksheet

Compare clinic and compounding pharmacy pricing for GLP-1 drugs on a like-for-like basis.

Guide

What Is 'Ozempic Face'?

The science behind facial volume loss on GLP-1 drugs. Applies to liraglutide as well as semaglutide.

---

References

1. [1]

   Pi-Sunyer X, Astrup A, Fujioka K, et al.. “A randomized, controlled trial of 3.0 mg of liraglutide in weight management.” N Engl J Med. 2015. 373(1):11-22 DOI PubMedRCT

   Landmark SCALE Obesity and Prediabetes trial. Phase III, double-blind, randomized, placebo-controlled. 3,731 participants across 191 sites in 27 countries. The trial that led to Saxenda approval.

2. [2]

   Marso SP, Daniels GH, Tanaka K, et al.. “Liraglutide and cardiovascular outcomes in type 2 diabetes.” N Engl J Med. 2016. 375(4):311-322 DOI PubMedRCT

   LEADER trial. 9,340 patients with T2D at high CV risk. Median follow-up 3.8 years. First GLP-1 receptor agonist to demonstrate cardiovascular benefit in a dedicated outcomes trial.

3. [3]

   Wadden TA, Hollander P, Klein S, et al.. “Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.” Int J Obes (Lond). 2013. 37(11):1443-1451 DOI PubMedRCT

   SCALE Maintenance trial. 422 participants. Demonstrated liraglutide's ability to maintain and extend diet-induced weight loss.

4. [4]

   Davies MJ, Bergenstal R, Bode B, et al.. “Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial.” JAMA. 2015. 314(7):687-699 DOI PubMedRCT

   SCALE Diabetes trial. 846 participants with T2D. Demonstrated significant weight loss and HbA1c improvement at 56 weeks.

5. [5]

   Knudsen LB, Lau J. “The discovery and development of liraglutide and semaglutide.” Front Endocrinol. 2019. 10:155 DOI PubMedReview

   Definitive account of liraglutide and semaglutide development from Novo Nordisk's GLP-1 analog program. Explains the chemistry behind the C-16 palmitic acid modification and why the C-18 diacid in semaglutide achieved longer half-life.

6. [6]

   Astrup A, Rossner S, Van Gaal L, et al.. “Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.” Lancet. 2009. 374(9701):1606-1616 DOI PubMedRCT

   Early Phase II dose-finding study for weight management. 564 participants. Identified the 3.0 mg dose as optimal for weight loss.

7. [7]

   le Roux CW, Astrup A, Fujioka K, et al.. “3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.” Lancet. 2017. 389(10077):1399-1409 DOI PubMedRCT

   3-year extension of the SCALE Obesity and Prediabetes trial. Showed sustained weight loss and 66% reduction in onset of type 2 diabetes vs. placebo.

8. [8]

   Kelly AS, Auerbach P, Barrientos-Perez M, et al.. “A randomized, controlled trial of liraglutide for adolescents with obesity.” N Engl J Med. 2020. 382(22):2117-2128 DOI PubMedRCT

   251 adolescents (12-17 years). Showed significant BMI reduction vs. placebo. Led to Saxenda pediatric approval (December 2020).

9. [9]

   Novo Nordisk. “Saxenda (liraglutide) injection 3 mg — full prescribing information.” 2024. Link

   FDA-approved prescribing information for chronic weight management. Includes black box warning for thyroid C-cell tumors observed in rodents.

10. [10]

    Novo Nordisk. “Victoza (liraglutide) injection — full prescribing information.” 2024. Link

    FDA-approved prescribing information for type 2 diabetes. Includes dosing, safety data, and black box warning.

---